227 related articles for article (PubMed ID: 30519760)
1. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
Nieveen van Dijkum EJM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
[No Abstract] [Full Text] [Related]
2. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
4. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
5. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
[TBL] [Abstract][Full Text] [Related]
6. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
[TBL] [Abstract][Full Text] [Related]
8. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
9. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Elevated Preoperative Specific Growth Rate is Associated with Shortened Survival After Resection for Pancreatic Neuroendocrine Tumors.
Baechle JJ; Marincola Smith P; Idrees K
Ann Surg Oncol; 2020 Oct; 27(10):3924-3925. PubMed ID: 32468347
[No Abstract] [Full Text] [Related]
12. Association of preoperative monocyte-to-lymphocyte and neutrophil-to-lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (US-NETSG).
Panni RZ; Lopez-Aguiar AG; Liu J; Poultsides GA; Rocha FG; Hawkins WG; Strasberg SM; Trikalinos NA; Maithel S; Fields RC;
J Surg Oncol; 2019 Sep; 120(4):632-638. PubMed ID: 31339198
[TBL] [Abstract][Full Text] [Related]
13. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
14. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
Bao F; Chen GR; Hui P; Cai GP
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
[No Abstract] [Full Text] [Related]
17. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.
Hamilton NA; Liu TC; Cavatiao A; Mawad K; Chen L; Strasberg SS; Linehan DC; Cao D; Hawkins WG
Surgery; 2012 Jul; 152(1):107-13. PubMed ID: 22503317
[TBL] [Abstract][Full Text] [Related]
19. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
20. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
Zaidi MY; Lopez-Aguiar AG; Switchenko JM; Lipscomb J; Andreasi V; Partelli S; Gamboa AC; Lee RM; Poultsides GA; Dillhoff M; Rocha FG; Idrees K; Cho CS; Weber SM; Fields RC; Staley CA; Falconi M; Maithel SK
Ann Surg; 2019 Sep; 270(3):422-433. PubMed ID: 31283562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
